Price to Operating Profit (P/OP)
since 2005
Paying user area
Try for free
Cytokinetics Inc. pages available for free this week:
- Balance Sheet: Assets
- Balance Sheet: Liabilities and Stockholders’ Equity
- Common Stock Valuation Ratios
- Enterprise Value to EBITDA (EV/EBITDA)
- Present Value of Free Cash Flow to Equity (FCFE)
- Selected Financial Data since 2005
- Operating Profit Margin since 2005
- Current Ratio since 2005
- Debt to Equity since 2005
- Price to Book Value (P/BV) since 2005
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Cytokinetics Inc. for $22.49.
This is a one-time payment. There is no automatic renewal.
We accept:
Calculation
Cytokinetics Inc., P/OP, long-term trends, calculation
| P/OP | = | Share price1, 2, 3 | ÷ | Operating profit per share1 | Operating profit per share1 | = | Operating income (loss)1 (in thousands) |
÷ | No. shares of common stock outstanding2 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 1, 2023 | = | ÷ | = | ÷ | |||||||
| Feb 25, 2022 | = | ÷ | = | ÷ | |||||||
| Feb 26, 2021 | = | ÷ | = | ÷ | |||||||
| Mar 4, 2020 | = | ÷ | = | ÷ | |||||||
| Mar 7, 2019 | = | ÷ | = | ÷ | |||||||
| Mar 5, 2018 | = | ÷ | = | ÷ | |||||||
| Mar 6, 2017 | = | ÷ | = | ÷ | |||||||
| Mar 3, 2016 | = | ÷ | = | ÷ | |||||||
| Mar 6, 2015 | = | ÷ | = | ÷ | |||||||
| Mar 7, 2014 | = | ÷ | = | ÷ | |||||||
| Mar 15, 2013 | = | ÷ | = | ÷ | |||||||
| Mar 13, 2012 | = | ÷ | = | ÷ | |||||||
| Mar 11, 2011 | = | ÷ | = | ÷ | |||||||
| Mar 11, 2010 | = | ÷ | = | ÷ | |||||||
| Mar 12, 2009 | = | ÷ | = | ÷ | |||||||
| Mar 12, 2008 | = | ÷ | = | ÷ | |||||||
| Mar 12, 2007 | = | ÷ | = | ÷ | |||||||
| Mar 10, 2006 | = | ÷ | = | ÷ |
Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).
1 US$
2 Data adjusted for splits and stock dividends.
3 Closing price as at the filing date of Cytokinetics Inc. Annual Report.
- Share Price
- The share price exhibited considerable volatility over the analyzed period. Starting at $42.90 in 2006, it declined sharply to a low point of $6.30 in 2013, reflecting a sustained negative trend over several years. After reaching this trough, the share price experienced partial recovery, increasing to $11.85 in 2017. However, this recovery was not linear, with intermittent decreases observed. From 2018 onwards, the share price showed a stronger upward trajectory, reaching a peak of $43.11 in early 2023, which surpasses the initial value recorded in 2006.
- Operating Profit Per Share (OPPS)
- Operating profit per share was predominantly negative throughout the period, indicating operational losses on a per-share basis. The losses slightly decreased from -$7.53 in 2006 to around -$0.38 in 2010, with an anomalous positive figure of $2.51 in the same year, suggesting a one-time gain or accounting adjustment. Subsequently, the losses resumed, although with some fluctuations between -$3.77 and -$0.38 until 2017. There was a brief positive figure of $0.45 in 2017, followed by a return to negative values, reaching -$3.41 in 2023, indicative of recurring operational challenges.
- Price to Operating Profit Ratio (P/OP)
- The P/OP ratio was only reported sporadically and exhibits considerable variation. A ratio of 8.04 was recorded in 2010, correlating with the unusual positive operating profit, while a significantly higher ratio of 26.46 appeared in 2018, despite a return to negative operating profits. This suggests that at times the market valuation of the company shares was disproportionately high relative to its operating earnings, likely reflecting speculative or forward-looking investor behavior in the face of volatile earnings.
Comparison to Competitors
Cytokinetics Inc., P/OP, long-term trends, comparison to competitors
| Cytokinetics Inc. | AbbVie Inc. | Amgen Inc. | Danaher Corp. | Gilead Sciences Inc. | Regeneron Pharmaceuticals Inc. | Thermo Fisher Scientific Inc. | Vertex Pharmaceuticals Inc. | |
|---|---|---|---|---|---|---|---|---|
| Mar 1, 2023 | ||||||||
| Feb 25, 2022 | ||||||||
| Feb 26, 2021 | ||||||||
| Mar 4, 2020 | ||||||||
| Mar 7, 2019 | ||||||||
| Mar 5, 2018 | ||||||||
| Mar 6, 2017 | ||||||||
| Mar 3, 2016 | ||||||||
| Mar 6, 2015 | ||||||||
| Mar 7, 2014 | ||||||||
| Mar 15, 2013 | ||||||||
| Mar 13, 2012 | ||||||||
| Mar 11, 2011 | ||||||||
| Mar 11, 2010 | ||||||||
| Mar 12, 2009 | ||||||||
| Mar 12, 2008 | ||||||||
| Mar 12, 2007 | ||||||||
| Mar 10, 2006 |
Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).